Clovis Oncology (CLVS) Misses Q2 EPS by 5c

Clovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($0.61), $0.05 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $36.82 million versus the consensus estimate of $41.12 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c